ArticleScience advances2024
Interferon response and epigenetic modulation by
Abstract read
In one paragraph
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Transposable Element Activation: A Hallmark of Cancer.Cancer discovery · 2026Review
- Regulation of immune checkpoint molecules in cancer immune evasion and therapy.Nature reviews. Cancer · 2026Review
- Therapeutic targeting of chromatin alterations in leukemia and solid tumors.International journal of cancer · 2026Review
- Immune checkpoint inhibitors have limited efficacy inTranslational lung cancer research · 2025Article
- Context-dependent impact of type I interferon signaling in cancer.Molecular cancer · 2025Review
- Review
- Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments.Trends in immunology · 2025Review
- Igniting Cold Tumors: Multi-Omics-Driven Strategies to Overcome Immune Evasion and Restore Immune Surveillance.Oncology research · 2025Review
- Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report.Human vaccines & immunotherapeutics · 2024Article
- Does an Autoimmune Disorder Following Ovarian Cancer Diagnosis Affect Prognosis?Current oncology (Toronto, Ont.) · 2024Article
Corrections and comments
- Update of
Authors and funding
25 authors.
Melica Nourmoussavi BrodeurDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7595-0313
Higinio DopesoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-0060-1861
Yingjie ZhuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1849-6019
Ana Leda F LonghiniFlow Cytometry Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrea GazzoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Siyu SunDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Richard P KocheCenter for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6820-5083
Rui QuAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0009-1185-9076
Laura RosenbergPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-3353-6402
Pierre-Jacques HamardCenter for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2484-6161
Yonina BykovDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hunter GreenDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0002-3944-6803
Laxmi GusainDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Katherine B ChiappinelliDepartment of Microbiology, Immunology and Tropical Medicine, The GW Cancer Center, The George Washington University, Washington, DC, USA.
Melih Arda OzsoyPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
M Herman ChuiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7220-3996
Thais BasiliDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3216-3544
Rui GardnerFlow Cytometry Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7270-5136
Sven WalderichDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-3671-3494
Elisa DeStanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3873-315X
Benjamin GreenbaumDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mithat GönenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8683-8477
Nicolas VabretPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Britta WeigeltDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9927-1270
Dmitriy ZamarinPrecision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0002-0094-0161
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MTranslational Immunology Training ProgramT32AI078892 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Karen Leigh Edelblum, SERGIO A. LIRA · 2008 to 2026
$4.5MPOTENTIATION OF ANTI-TUMOR IMMUNITY BY ONCOLYTIC VIRUS IN SITU VACCINATIONR01CA269382 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Dmitriy Zamarin · 2023 to 2026
$2.5MExamining multilevel associations in dental researchR03DE019805 · NIDCR · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI STONER, JULIE A · 2010 to 2011
$308kNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA269382NIAID NIH HHS T32 AI078892NIDCR NIH HHS R03 DE019805
Abstract
Cell-intrinsic mechanisms of immunogenicity in ovarian cancer (OC) are not well understood. Damaging mutations in the SWI/SNF chromatin remodeling complex, such as
Indexed as
DNA HelicasesEpigenesis, GeneticMutationNuclear ProteinsOvarian NeoplasmsTranscription FactorsAnimalsCell Line, TumorDisease Models, AnimalFemaleGene Expression Regulation, NeoplasticHumansInterferonsMiceSignal TransductionTumor MicroenvironmentDNA HelicasesInterferonsNuclear ProteinsSMARCA4 protein, humanSmarca4 protein, mouseTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.